Real-World Study Explores BTK Inhibitor Trends for CLL, SLL | Blood Cancers Today
Over a three-year study period ibrutinib use in the US decreased while acalabrutinib and zanubrutinib use increased.
Over a three-year study period ibrutinib use in the US decreased while acalabrutinib and zanubrutinib use increased.
Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding
An abstract is unavailable.
Neoadjuvant sotigalimab plus chemoradiotherapy is safe and feasible compared with chemoradiotherapy alone in patients with rectal cancer.
FDA Oncology Center of Excellence Presents: Conversations on Cancer: “Pazdur + 25—Celebrating a Silver FDA Anniversary”
Noah M. Merin, MD, PhD, discusses the mechanisms of action and sequencing of oral therapies for chronic graft-vs-host disease (GVHD) in a live virtual event.
Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.
You Know I Know. The brand new album. OUT NOW: http://smarturl.it/ykikdlxYTDStream the album in full on Spotify here: http://smarturl.it/OMMusicPlaylist Kee…
ASTCT introduces the Gene Therapy Summit, an interactive meeting of representatives from academic and clinical centers, the biotechnology industry, ASTCT and additional collaborative professional societies…
Survey results suggest that cancer patients want financial toxicity screening to occur early, but screening preferences and practices vary.